# Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

> **NCT02921256** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 363 (actual)

## Conditions studied

- Rectal Adenocarcinoma
- Stage II Rectal Cancer AJCC v7
- Stage III Rectal Cancer AJCC v7

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Fluorouracil
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT02921256
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-11
- **Primary completion:** 2020-04-21
- **Final completion:** 2023-09-20
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02921256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02921256, "Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT02921256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*